CKPT

CHECKPOINT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Samstag, Juni 1, 2024
Patient, News, Food, FDA, Telephone, Person, Radiation, CMO, Biologics license application, Acquisition, Court, CRL, P.C, BLA, CKPT, District court, Complaint, Pharmaceutical industry

Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Checkpoint's lead antibody product candidate is cosibelimab for the treatment of selected recurrent or metastatic cancers.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)

Retrieved on: 
Freitag, Mai 31, 2024
News, Food, Suite, FDA, Checkpoint, CMO, Defendant, Biologics license application, Court, BLA, CKPT, GPM

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Checkpoint securities during the Class Period, you may move the Court no later than June 4, 2024 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Holzer & Holzer, LLC Reminds Shareholders of June 4, 2024 Lead Plaintiff Deadline in Checkpoint Therapeutics, Inc. (CKPT) Class Action – Nationally Ranked Investors’ Rights Firm Encourages Investors With Losses in Excess of $300,000 to Contact the Firm

Retrieved on: 
Donnerstag, Mai 30, 2024
BLA, ISS, Checkpoint, FDA, CKPT, Fraud

ATLANTA, May 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT).

Key Points: 
  • ATLANTA, May 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT).
  • The deadline to ask the court to be appointed lead plaintiff in the case is June 4, 2024.
  • More information about the firm is available through its website, www.holzerlaw.com , and upon request from the firm.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT

Retrieved on: 
Donnerstag, Mai 30, 2024
Titan, Class, Advertising, Checkpoint, Court, CKPT, Food and Drug Administration

WHAT TO DO NEXT: To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Retrieved on: 
Donnerstag, Mai 30, 2024
Patient, News, Advertising, FDA, Radiation, CMO, LLP, Court, CRL, BLA, CKPT, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Checkpoint’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • To learn more about the Checkpoint Therapeutics class action, go to www.faruqilaw.com/CKPT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Retrieved on: 
Dienstag, Mai 28, 2024
Patient, News, Food, FDA, Prior, Person, Radiation, Checkpoint, Ext, CMO, Pomerantz, Biologics license application, Acquisition, LLP, Court, Action Replay, BLA, CKPT, District court, Complaint

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Retrieved on: 
Dienstag, Mai 28, 2024
Suite, FDA, Ethics, Certification, CKPT, Complaint, Security (finance)

Investors who purchased the Company’s securities between March 10, 2021 and December 15, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 4, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between March 10, 2021 and December 15, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 4, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT

Retrieved on: 
Montag, Mai 27, 2024
Titan, Class, Advertising, Checkpoint, Court, CKPT, Food and Drug Administration

WHAT TO DO NEXT: To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Montag, Mai 27, 2024
Patient, News, FDA, Person, Radiation, CMO, Court, CRL, BLA, CKPT, Complaint

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT

Retrieved on: 
Donnerstag, Mai 23, 2024
Titan, Class, Advertising, Checkpoint, Court, CKPT, Food and Drug Administration

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.